Usana Health Sciences Inc 8-K, filed Jun 29, 2020
Usana Health Sciences Inc (USNA)
8-K
2020-06-29
For: 2020-06-24
View Original
Added on
April 06, 2026
About this 8-K
Usana Health Sciences Inc filed this 8-K on June 29, 2020, reporting on events of June 24, 2020.
Items reported
- Item 7.01: Regulation FD disclosure
- Item 8.01: Other events
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Washington, D.C. 20549
_________________
FORM 8-K
_________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation)
|
|
|
|
|
(Commission File No.)
|
(IRS Employer
Identification No.)
|
(Address of principal executive offices, Zip Code)
Registrant's telephone number, including area code: (801 ) 954-7100
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined
in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure
The information disclosed below under Item 8.01is incorporated herein by reference.
Item 8.01 Other Events
In a Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 7, 2017, the Company disclosed that it was conducting a voluntary
internal investigation regarding its BabyCare operations in China. The investigation focused on compliance with the Foreign Corrupt Practices Act and certain conduct and policies at BabyCare. Also in 2017, the Company voluntarily contacted the SEC
and the United States Department of Justice (“DOJ”) to advise both agencies that an internal investigation was underway. The Company subsequently provided additional information to both agencies and has cooperated with both agencies since first
advising them of the investigation. As a result of the internal investigation, the Company implemented a number of actions to remediate the issues discovered during the internal investigation, all of which have been previously disclosed by the
Company in its Annual Report on Form 10-K for the fiscal year 2017, which the Company filed with the SEC on February 28, 2018.
On June 24, 2020, the SEC informed the Company that it had closed its investigation and declined any enforcement action. The SEC stated that it had reached
this conclusion based on a number of factors, including, but not limited to, the Company’s (i) prompt, voluntary self-disclosure of the matters underlying the investigation, (ii) thorough internal investigation, (iii) full cooperation with the SEC,
and (iv) remediation of the matters underlying the investigation.
On June 26, 2020, the DOJ informed the Company by letter that it had closed its investigation into this matter, noting the Company’s cooperation during the
investigation.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
USANA HEALTH SCIENCES, INC.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ G. Douglas Hekking
|
|
|
|
G. Douglas Hekking, Chief Financial Officer
|
||
Date: June 29, 2020